Both Amarin Corporation plc (NASDAQ:AMRN) and Applied Genetic Technologies Corporation (NASDAQ:AGTC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amarin Corporation plc | 19 | 18.12 | N/A | -0.38 | 0.00 |
| Applied Genetic Technologies Corporation | 4 | 1.18 | N/A | 0.10 | 39.39 |
Demonstrates Amarin Corporation plc and Applied Genetic Technologies Corporation earnings per share (EPS), top-line revenue and valuation.
Profitability
Table 2 hightlights the net margins, return on assets and return on equity of the two companies.
| Net Margins | Return on Equity | Return on Assets | |
| Amarin Corporation plc | 0.00% | -450.1% | -39.8% |
| Applied Genetic Technologies Corporation | 0.00% | 2.2% | 1.7% |
Risk and Volatility
Amarin Corporation plc has a 1.13 beta, while its volatility is 13.00% which is more volatile than Standard & Poor’s 500. Competitively, Applied Genetic Technologies Corporation’s 151.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.51 beta.
Liquidity
The Current Ratio of Amarin Corporation plc is 2.2 while its Quick Ratio stands at 1.8. The Current Ratio of rival Applied Genetic Technologies Corporation is 10.9 and its Quick Ratio is has 10.9. Applied Genetic Technologies Corporation is better equipped to clear short and long-term obligations than Amarin Corporation plc.
Analyst Recommendations
The following table delivered below contains the ratings and recommendations for Amarin Corporation plc and Applied Genetic Technologies Corporation.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Amarin Corporation plc | 0 | 0 | 4 | 3.00 |
| Applied Genetic Technologies Corporation | 0 | 0 | 0 | 0.00 |
Amarin Corporation plc has a 129.76% upside potential and a consensus price target of $35.75.
Insider & Institutional Ownership
The shares of both Amarin Corporation plc and Applied Genetic Technologies Corporation are owned by institutional investors at 45.5% and 55.1% respectively. Amarin Corporation plc’s share held by insiders are 0.8%. Competitively, insiders own roughly 0.5% of Applied Genetic Technologies Corporation’s shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Amarin Corporation plc | 0.11% | -3.38% | 6.11% | 9.74% | 658.78% | 36.59% |
| Applied Genetic Technologies Corporation | -3.98% | 4.32% | -8.31% | 30.41% | -5.28% | 55.02% |
For the past year Amarin Corporation plc was less bullish than Applied Genetic Technologies Corporation.
Summary
Applied Genetic Technologies Corporation beats Amarin Corporation plc on 6 of the 9 factors.
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The companyÂ’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
